Traders See Bullish Options Activity Eagle Pharmaceuticals Inc

 Traders See Bullish Options Activity Eagle Pharmaceuticals Inc

In today’s session Eagle Pharmaceuticals Inc (EGRX) registered an unusually high (229) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the March, 2017 call, expecting serious EGRX increase. With 229 contracts traded and 814 open interest for the Mar, 17 contract, it seems this is a quite bullish bet. The option with symbol: EGRX170317C00075000 closed last at: $9.7 or 21.2% up. About 247,821 shares traded hands. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 91.42% since April 5, 2016 and is uptrending. It has outperformed by 89.46% the S&P500.

Analysts await Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to report earnings on November, 9. They expect $0.84 earnings per share, up 229.23% or $1.49 from last year’s $-0.65 per share. EGRX’s profit will be $13.02 million for 21.88 P/E if the $0.84 EPS becomes a reality. After $0.80 actual earnings per share reported by Eagle Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 5.00% EPS growth.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Ratings Coverage

Out of 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Eagle Pharma has been the topic of 9 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm earned “Overweight” rating on Wednesday, July 29 by Piper Jaffray. RBC Capital Markets maintained the shares of EGRX in a report on Thursday, November 3 with “Outperform” rating. The firm has “Buy” rating given on Friday, February 26 by Mizuho. Mizuho upgraded it to “Buy” rating and $78 target price in Thursday, November 3 report. The firm has “Outperform” rating given on Wednesday, November 2 by William Blair. The firm earned “Buy” rating on Wednesday, October 26 by Mizuho. Mizuho downgraded Eagle Pharmaceuticals Inc (NASDAQ:EGRX) on Monday, June 20 to “Neutral” rating. Mizuho initiated Eagle Pharmaceuticals Inc (NASDAQ:EGRX) on Wednesday, December 9 with “Buy” rating. RBC Capital Markets maintained Eagle Pharmaceuticals Inc (NASDAQ:EGRX) on Tuesday, May 10 with “Outperform” rating.

According to Zacks Investment Research, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.”

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $1.14 billion. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. It has a 461.58 P/E ratio. The Company’s product portfolio includes EP-1101 ; Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

EGRX Company Profile

Eagle Pharmaceuticals, Inc., incorporated on January 2, 2007, is a specialty pharmaceutical company. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). The Firm has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). The Company’s near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.

More news for Eagle Pharmaceuticals Inc (NASDAQ:EGRX) were recently published by: Fool.com, which released: “Why Eagle Pharmaceuticals, Inc. Is Soaring 21.6% Today” on November 02, 2016. Fool.com‘s article titled: “Why Eagle Pharmaceuticals Inc. Flew 38.5% Higher in August” and published on September 09, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment